

Bio-Gene Technology Limited I ASX: BGT

Annual General Meeting

Developing new insecticides derived from nature to achieve high impact worldwide.

FY2024

Presentation

Tim Grogan
Managing Director & CEO



Important Notice & Disclaimer

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitution a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. no representation, warranty or guarantee, express or implied, is given that any Forward-Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward-Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.



Contents



Company Highlights	04.
Product Overview	05.
Commercial Strategy	06.
Milestones & News Flow	14.

Company Highlights

Focused development of two new insecticides with strong commercial validation.

01. Two New Actives

Late-stage development: two insecticidal compounds derived from nature with novel modes of action:

- » Flavocide® and Qcide® are derived from a unique sub-type of eucalypt
- » effectiveness against some major insect pests with resistance to standard products
- » Strong drivers are increasing the demand for safer and more environmentally friendly products

02. Large Target Markets

Crop Protection (incl. Grain Storage), **Public Health, Consumer, Animal Health,** total addressable markets of \$31B, as **both stand-alone** and **combination** products¹

03. Focused Pipeline

Pipeline of eight (formulated) product opportunities:


- » Public Health vectors for disease
- » Crop Protection, Aquaculture, Professional Turf and Ornamentals
- » Grain Storage Protection
- » Consumer (home & garden)


04. Strong Partnering Progress

Three partnerships to date:

» Clarke Mosquito (US), Evergreen Garden Care (EU, UK, AU & NZ), STK (Israel)







Our Unique Products Derived from Nature

01

Qcide®

Qcide is an 100% natural oil extracted from the leaves of a specific cultivar of eucalypt (*Gypmie messmate*) currently farmed in northern Australia.

✓ 12th harvest in QLD completed in 2024



Flavocide®

Flavocide is based on flavesone, a naturally occurring plant compound synthesised via a proprietary process that allows production in large volumes for global demand.

✓ Pilot-scale production completed at Rallis India Ltd.

Patent families owned by Bio-Gene include: (1) Control of resistant pests.(2) Use in synergistic combinations, (3) Control of specific pests e.g., aphids, (4) Ovicidal activity against insect pests e.g., mites, bed bugs. Territories: Australia & New Zealand, USA/Europe, Latin America (Brazil), Asia (China), Africa (RSA)









Flavocide & Qcide - Multiple Market Segments

Bio-Gene is targeting five large well-developed global markets

Sectors		*	•		
	Crop Protection	Grain Storage	Public Health	Consumer Applications	Animal Health
	Food & Fibre	Stored Grain	Vector Control for Malaria, Zika & Dengue	Urban Pest Management, Oils, Lotions & Personal Repellents	Livestock & Pet-care Products
Size (US\$) & % of \$31.1B	\$16.1B 52%	\$1.0B 3%	\$4.0B 13%	\$4.1B 13%	\$5.9B 19%
Current Products & Challenges	EU import restrictions (e.g. Omethoate for red- legged earth mite in Canola) Secondary regulation imposed by food chain (Aldi) Consumer and regulatory pressures	Pyrethroids, phosphine, organophosphates, etc. High levels of resistance in lesser grain borer, flat grain beetle, rice weevil	e.g. Bifenthrin, deltamethrin, pyrethrins, etc. Mosquito control market projected to grow by 38% between 2021-26 ¹	Mineral oils, toxic synthetics (e.g. malathion), pyrethum based products etc. Home and garden uses, Shift towards safe (especially to children & pets) and eco-friendly products to protect the environment	Japanese Encephalitis outbreaks Prevalence of ticks Consumer concerns for pet health

^{1.} Global Mosquito Control Professional Survey Report 2021, Forecast to 2026)



Flavocide & Qcide – Our Pipeline

Bio-Gene is targeting five large well-developed global markets


Active constituent	Description		Sectors	Target uses	Partners & Collaborators
Flavocide	1	Grain Protectant	Crop protection	Admixture to grain	GRDC GRAINS RESEARCH & DEVELOPMENT CORPORATION
	2	Outdoor Space Spray	Public health	Flying insects	Ф скогке
	3	Indoor Barrier Spray	Public health	Flying & crawling insects	SUV O.
	4	Outdoor Barrier Spray	Public health	Flying & crawling insects	⇔ с с с с с с с с с с с с с с с с с
	5	Indoor Space Spray	Consumer	Flying insects	EVERGREEN Garden Care
Qcide	6	Indoor Space Spray	Consumer	Flying insects	
	7	Outdoor Barrier Spray	Consumer	Flying insects	
	8	Outdoor Garden Spray	Crop protection & Consumer	Fruit & vegetables, ornamentals	EVERGREEN Garden Care bio-ag technologies

BGT is also investigating other potential use patterns, product extensions and combinations with other active ingredients.



Flavocide Development Path

Regulatory approval of a formulated product is a two-step process.



FY24 & Recent Achievements

8 August 2024

Study plans for Flavocide on track following APVMA feedback

ASX ANNOUNCEMENT 8 August 2024 BIO-GENE TECHNOLOGY

Bio-Gene's registration plans for Flavocide® on track following APVMA feedback

Highlights

- Studies planned for the Flavocide® insect control active ingredient regulatory dossier
 are confirmed following feedback received from the Australian Pesticides and
 Veterinary Medicines Authority (APVMA)
- APVMA provides assistance on the regulatory requirements to facilitate registration of new active ingredients
- Flavocide is a novel insecticidal active ingredient derived from nature being developed by Bio-Gene for use in public health, agriculture and by consumers



Australian Government

Australian Pesticides and Veterinary Medicines Authority 14 August 2024

Envu collaboration to evaluate Flavocide for mosquito management





ANNOUNCEMEN

14 August 2024

Bio-Gene and Envu collaborate to evaluate Flavocide™ for use in public and private sector mosquito management

Highlights

- Joint collaboration evaluating Flavocide[™] for mosquito management across a range of professional applications
- Flavocide complements the product pipeline of forward-thinking effective chemistries Envu offers for the global professional non-crop market
- Flavocide shown to effectively control mosquitoes

2 September 2024

Flavocide production successful at pre-commercial scale





ASX ANNOUNCEMENT 2 September 2024

Bio-Gene and Rallis India Limited achieve key Flavocide® production milestone

Highlight

- Successful pilot-scale production of Flavocide® conducted by Rallis India Limited, one of India's leading Agri-sciences companies and a subsidiary of Tata Chemicals Limited
- Demonstration that Flavocide® can be produced at a consistent quality and yield at precommercial scale
- Flavocide® produced by Rallis India Limited to be used in planned testing activities to advance the registration process for Flavocide®
- Capacity to produce Flavocide® in sufficient quantities for future supply to Bio-Gene's commercial licensees



Bio-Gene's Strategic Priorities

Strategy is focused on efficient development and approval of Flavocide and Qcide, with more commercial partnerships.

Speed

Particularly the pre-registration manufacturing and safety studies for Flavocide and Qcide active ingredients.

Build Bio-Gene's Profile

Efficient Use of Capital

To leverage the funding from shareholders wherever possible with partner contributions and grants.

Commercial Validation

To build on existing commercial partnerships and secure the resources of additional larger partners and funding organisations to support the development of additional commercially attractive botanically derived insecticides.

Focused Product Development

To deploy our resources against a pipeline of the most commercially attractive development products and partnered programs (both as stand-alone and combination products) that can be developed as soon as possible.

Key Forward Milestones & News Flow

Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow.



Flavocide & Qcide development

- ✓ Flavocide regulatory studies (multiple)
- ✓ Submission of Flavocide regulatory dossier in Australia
- ✓ Flavocide scale-up milestones
- ✓ Qcide regulatory development milestones
- ✓ Qcide scale-up and harvest/processing progress
- ✓ Regulatory milestones



Partnering & commercial

- ✓ New commercial partnerships
 - Crop & grain storage
 - Vector control
 - Consumer uses
- ✓ Expansion of current licenses
- ✓ Receipt of milestone payments
- ✓ Patents granted

03

Funding & other support

- ✓ Grant funding successes
- ✓ Synergistic program/product opportunities
- ✓ International funding support & validation



Questions?

Contact

Tim Grogan Managing Director & CEO timg@bio-gene.com.au

Matthew Wright NWR Communications matt@nwrcommunications.com.au 0451 896 420



Proxy Summary Report as at 27-Nov-24

